Omeros Shares Outstanding 2012-2025 | OMER
Omeros shares outstanding from 2012 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Omeros Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2024 | 58 |
| 2023 | 63 |
| 2022 | 63 |
| 2021 | 62 |
| 2020 | 57 |
| 2019 | 50 |
| 2018 | 49 |
| 2017 | 46 |
| 2016 | 40 |
| 2015 | 38 |
| 2014 | 33 |
| 2013 | 29 |
| 2012 | 24 |
| 2011 | 22 |
|
Omeros Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025-09-30 | 66 |
| 2025-06-30 | 59 |
| 2025-03-31 | 58 |
| 2024-12-31 | 58 |
| 2024-09-30 | 58 |
| 2024-06-30 | 58 |
| 2024-03-31 | 59 |
| 2023-12-31 | 63 |
| 2023-09-30 | 63 |
| 2023-06-30 | 63 |
| 2023-03-31 | 63 |
| 2022-12-31 | 63 |
| 2022-09-30 | 63 |
| 2022-06-30 | 63 |
| 2022-03-31 | 63 |
| 2021-12-31 | 62 |
| 2021-09-30 | 63 |
| 2021-06-30 | 62 |
| 2021-03-31 | 62 |
| 2020-12-31 | 57 |
| 2020-09-30 | 58 |
| 2020-06-30 | 55 |
| 2020-03-31 | 54 |
| 2019-12-31 | 50 |
| 2019-09-30 | 49 |
| 2019-06-30 | 49 |
| 2019-03-31 | 49 |
| 2018-12-31 | 49 |
| 2018-09-30 | 49 |
| 2018-06-30 | 48 |
| 2018-03-31 | 48 |
| 2017-12-31 | 46 |
| 2017-09-30 | 46 |
| 2017-06-30 | 44 |
| 2017-03-31 | 44 |
| 2016-12-31 | 40 |
| 2016-09-30 | 41 |
| 2016-06-30 | 39 |
| 2016-03-31 | 38 |
| 2015-12-31 | 38 |
| 2015-09-30 | 38 |
| 2015-06-30 | 38 |
| 2015-03-31 | 36 |
| 2014-12-31 | 33 |
| 2014-09-30 | 34 |
| 2014-06-30 | 34 |
| 2014-03-31 | 31 |
| 2013-12-31 | 29 |
| 2013-09-30 | 30 |
| 2013-06-30 | 28 |
| 2013-03-31 | 26 |
| 2012-12-31 | 24 |
| 2012-09-30 | 26 |
| 2012-06-30 | 22 |
| 2012-03-31 | 22 |
| 2011-12-31 | 22 |
| 2011-09-30 | 22 |
| 2011-06-30 | 22 |
| 2011-03-31 | 22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.796B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $192.719B | 21.52 |
| EssilorLuxottica (ESLOY) | France | $140.970B | 0.00 |
| Stryker (SYK) | United States | $137.019B | 26.29 |
| Medtronic (MDT) | Ireland | $131.919B | 18.28 |
| Boston Scientific (BSX) | United States | $113.066B | 25.01 |
| Medline (MDLN) | United States | $62.139B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.969B | 0.00 |
| ResMed (RMD) | United States | $39.571B | 26.42 |
| GE HealthCare Technologies (GEHC) | United States | $36.756B | 17.61 |
| Agilent Technologies (A) | United States | $36.736B | 23.22 |
| Koninklijke Philips (PHG) | Netherlands | $28.368B | 18.53 |
| Terumo (TRUMY) | Japan | $19.441B | 21.97 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.819B | 11.11 |
| Insulet (PODD) | United States | $17.019B | 52.82 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.739B | 0.00 |
| Baxter (BAX) | United States | $11.170B | 9.02 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.133B | 29.24 |
| Demant (WILYY) | Denmark | $6.521B | 0.00 |
| Envista Holdings (NVST) | United States | $4.785B | 24.25 |
| Lantheus Holdings (LNTH) | United States | $4.303B | 13.11 |
| BillionToOne (BLLN) | United States | $4.147B | 0.00 |
| ICU Medical (ICUI) | United States | $3.806B | 24.16 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.263B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.189B | 14.81 |
| Haemonetics (HAE) | United States | $2.778B | 12.06 |
| Neogen (NEOG) | United States | $2.349B | 51.43 |
| Phibro Animal Health (PAHC) | United States | $2.151B | 18.95 |
| Perrigo (PRGO) | Ireland | $2.015B | 5.05 |
| LeMaitre Vascular (LMAT) | United States | $1.983B | 39.92 |
| QuidelOrtho (QDEL) | United States | $1.977B | 12.71 |
| AtriCure (ATRC) | United States | $1.845B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.622B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.486B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.475B | 64.64 |
| AdaptHealth (AHCO) | United States | $1.442B | 20.88 |
| Capricor Therapeutics (CAPR) | United States | $1.130B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.080B | 320.43 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.021B | 0.00 |
| InMode (INMD) | Israel | $0.953B | 10.77 |
| Tilray Brands (TLRY) | Canada | $0.883B | 0.00 |
| Valneva SE (VALN) | France | $0.817B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.803B | 0.00 |
| CeriBell (CBLL) | United States | $0.747B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.587B | 15.91 |
| Verano Holdings (VRNO) | United States | $0.454B | 0.00 |
| Brainsway (BWAY) | Israel | $0.427B | 72.60 |
| Cerus (CERS) | United States | $0.423B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.405B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.377B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.328B | 26.18 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Evolus (EOLS) | United States | $0.292B | 0.00 |
| Quanterix (QTRX) | United States | $0.284B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.222B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.207B | 0.00 |
| High Tide (HITI) | Canada | $0.207B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.197B | 17.71 |
| Aurora Cannabis (ACB) | Canada | $0.197B | 58.00 |
| OraSure Technologies (OSUR) | United States | $0.194B | 0.00 |
| Accendra Health (ACH) | United States | $0.185B | 1.85 |
| Sanara MedTech (SMTI) | United States | $0.180B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.179B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.144B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.136B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.72 |
| MacroGenics (MGNX) | United States | $0.115B | 0.00 |
| Biote (BTMD) | United States | $0.102B | 4.46 |
| Jushi Holdings (JUSHF) | United States | $0.100B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| ImmuCell (ICCC) | United States | $0.056B | 24.00 |
| Sharps Technology (STSS) | United States | $0.048B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.042B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 29.77 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.033B | 16.63 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| ZeroStack (ZSTK) | United States | $0.010B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |